title: The effects of methamphetamine self-administration on cortical monoaminergic deficits induced by subsequent high-dose methamphetamine administrations.
abstract: Preclinical models suggest that repeated high-dose methamphetamine (METH) exposures, administered in a "binge-like" pattern, acutely decrease norepinephrine (NE), and acutely and persistently decrease serotonin (5-hydroxytryptamine; 5HT) content in the frontal cortex. However, the impact of METH self-administration on this region is unknown. Because of the importance of the monoaminergic neurons in the frontal cortex to a variety of cognitive and addictive processes, effects of METH self-administration on cortical NE and 5HT content were assessed. Results revealed several novel findings. First, METH self-administration decreased cortical NE content as assessed 24 h after last exposure. Consistent with previous preclinical reports after a binge METH regimen, this decrease was reversed 8 days after the final METH exposure. Second, and in contrast to our previous reports involving the hippocampus or striatum, METH self-administration caused persistent decreases in 5HT content as assessed 8 days after the final METH exposure. Of note, the magnitude of this decrease (≈ 20%) was less than that observed typically after a binge METH treatment. Third, prior METH self-administration attenuated METH-induced serotonergic deficits as assessed 7 days, but not 1 h, following a neurotoxic METH regimen. No protection was observed when the binge exposure occurred 15 days after the last self-administration session. Taken together, these data demonstrate important and selective alterations in cortical serotonergic neuronal function subsequent to METH self-administration. These data provide a foundation to investigate complex questions involving "resistance" to the persistent deficits caused by neurotoxic METH exposure and frontal cortical function.
authors.affiliation: Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah, 84112.
authors.forename: Lisa M
authors.initials: LM
authors.lastname: McFadden
authors.forename: Glen R
authors.initials: GR
authors.lastname: Hanson
authors.forename: Annette E
authors.initials: AE
authors.lastname: Fleckenstein
mesh_terms: D000818:Animals; D002540:Cerebral Cortex / Q000737:chemistry / Q000187:drug effects*; D008297:Male; D008694:Methamphetamine / Q000008:administration & dosage / Q000494:pharmacology*; D009638:Norepinephrine / Q000172:deficiency* / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D012646:Self Administration; D012701:Serotonin / Q000172:deficiency* / Q000378:metabolism
chemical_list: D012701:Serotonin; D008694:Methamphetamine; D009638:Norepinephrine
keywords: cortex; methamphetamine; norepinephrine; self-administration; serotonin
references.citation: Synapse. 2006 Dec 1;60(7):521-32
references.pmid: 16952162
references.citation: J Psychopharmacol. 2008 Jan;22(1):100-10
references.pmid: 18187537
references.citation: Ann N Y Acad Sci. 2010 Feb;1187:101-21
references.pmid: 20201848
references.citation: Compr Psychiatry. 2006 May-Jun;47(3):215-20
references.pmid: 16635651
references.citation: Neuropsychopharmacology. 2010 Jan;35(1):217-38
references.pmid: 19710631
references.citation: Nat Rev Neurosci. 2011 Oct 20;12(11):652-69
references.pmid: 22011681
references.citation: Synapse. 2010 Aug;64(8):579-93
references.pmid: 20340164
references.citation: Neuropsychopharmacology. 2005 Feb;30(2):296-309
references.pmid: 15483559
references.citation: Neurotox Res. 2009 Apr;15(3):252-9
references.pmid: 19384598
references.citation: Brain Res. 2010 Mar 4;1317:137-46
references.pmid: 19962371
references.citation: Neuropharmacology. 2012 Feb;62(2):1119-26
references.pmid: 22115899
references.citation: Pharmacol Biochem Behav. 1998 Sep;61(1):35-44
references.pmid: 9715805
references.citation: Eur J Pharmacol. 1989 Mar 7;172(1):93-7
references.pmid: 2714371
references.citation: Biol Psychiatry. 2008 Dec 1;64(11):958-65
references.pmid: 18490002
references.citation: Int Rev Neurobiol. 2009;88:65-100
references.pmid: 19897075
references.citation: Annu Rev Neurosci. 2009;32:267-87
references.pmid: 19555290
references.citation: J Pharmacol Exp Ther. 1997 Oct;283(1):281-5
references.pmid: 9336334
references.citation: Psychopharmacology (Berl). 2012 Jan;219(2):411-20
references.pmid: 21643674
references.citation: Cereb Cortex. 2007 Sep;17 Suppl 1:i151-60
references.pmid: 17725997
references.citation: Eur J Pharmacol. 1997 Apr 18;324(2-3):179-86
references.pmid: 9145769
references.citation: Psychopharmacology (Berl). 2007 Oct;194(3):321-31
references.pmid: 17589830
references.citation: Neuropharmacology. 2011 Sep;61(3):382-6
references.pmid: 21251917
references.citation: J Neurochem. 2000 Nov;75(5):2095-102
references.pmid: 11032899
references.citation: Nat Med. 1996 Jun;2(6):699-703
references.pmid: 8640565
references.citation: Synapse. 2008 Mar;62(3):193-204
references.pmid: 18081184
references.citation: J Neurosci Methods. 1980 Dec;3(2):129-49
references.pmid: 6110810
references.citation: J Pharmacol Exp Ther. 2012 Feb;340(2):295-303
references.pmid: 22034657
references.citation: Synapse. 2009 Oct;63(10):881-94
references.pmid: 19582783
references.citation: Neurobiol Learn Mem. 2011 Oct;96(3):417-31
references.pmid: 21855643
references.citation: Annu Rev Pharmacol Toxicol. 2007;47:681-98
references.pmid: 17209801
references.citation: PLoS One. 2010 Jan 20;5(1):e8790
references.pmid: 20098750
references.citation: Arch Gen Psychiatry. 2006 Jan;63(1):90-100
references.pmid: 16389202
references.citation: Synapse. 2012 Jan;66(1):71-80
references.pmid: 21953518
references.citation: Neuroscience. 2012 Feb 17;203:99-107
references.pmid: 22245499
references.citation: Neuropsychology. 2007 Mar;21(2):251-62
references.pmid: 17402825
references.citation: Eur J Pharmacol. 2007 Mar 15;559(1):46-54
references.pmid: 17239369
references.citation: J Neurochem. 2012 Sep;122(5):995-1009
references.pmid: 22776046
references.citation: Eur J Pharmacol. 2003 Dec 15;482(1-3):151-4
references.pmid: 14660016
references.citation: J Pharmacol Exp Ther. 2011 Mar;336(3):809-15
references.pmid: 21131268
references.citation: Psychiatry Res. 2011 Dec 30;194(3):287-295
references.pmid: 22047731
references.citation: Psychoneuroendocrinology. 2010 May;35(4):629-33
references.pmid: 19879056
references.citation: Biol Psychiatry. 2011 Feb 1;69(3):253-9
references.pmid: 21051037
references.citation: Neuropharmacology. 2013 Apr;67:95-103
references.pmid: 23159331
references.citation: Drug Alcohol Rev. 2010 Jan;29(1):12-20
references.pmid: 20078677
references.citation: Psychopharmacology (Berl). 2012 Dec;224(3):459-67
references.pmid: 22760483
references.citation: J Neurochem. 2008 Jun;105(5):1873-85
references.pmid: 18248616
references.citation: Biol Psychiatry. 2011 Jun 15;69(12):e89-99
references.pmid: 21489408
references.citation: Drug Alcohol Depend. 2012 Nov 1;126(1-2):87-94
references.pmid: 22647900